Trial Type: Liver and Bile Duct Cancer

LS-P-ROSE
A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC
Status: Open
Trial Type: Liver and Bile Duct Cancer
Contact: Khaldoun Almhanna, MD
kalmhanna@brownhealth.org
GPC3CD3 Trial
A phase 1/2 study of SAR444200, an anti-GPC3/CD3 bispecific antibody in patients with advanced solid tumors
Status: Open
Trial Type: Colon Cancer, Esophageal Cancer, Liver and Bile Duct Cancer
Contact: Khaldoun Almhanna, MD
kalmhanna@brownhealth.org
PORT
GPC3/CD3 bispecific antibody for all solid tumors with GPC3 expression.
Status: Open
Trial Type: Early Phase Trials for Multiple Cancer Types, Liver and Bile Duct Cancer
Contact: Khaldoun Almhanna, MD
kalmhanna@brownhealth.org

©2025 Brown Cancer Trials